A Phase 4 interventional study of Fentanyl buccal soluble film in Breakthrough Cancer Pain, sponsored by Chang Gung Memorial Hospital. Recruiting at 4 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Chang Gung Memorial Hospital · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Cancer Pain with a site in Taiwan — 4 open to participants now, 4 under way, none of them phase 3. Cancer Pain · Taiwan.
Among the 19 studies in Cancer Pain with a site in Taiwan, this one has the largest planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 4, and was the 19th registered.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
Browse Cancer Pain studies →4 of the 19 studies in Cancer Pain with a site in Taiwan are open now. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–80
Kaohsiung Veterans General Hospital. · Sites in Taiwan
Ages 20–100
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 44 Cancer Pain studies recruiting now, 32 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,073 is above the median of 63 across 236 interventional studies indexed under Cancer Pain.
Median enrollment 89 across the 14 interventional studies, 83 across the 5 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 19 have an industry lead sponsor. The 10 most frequent:
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
Chang Gung Memorial Hospital has 4 studies filed under Cancer Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Cancer Pain with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to develop and test a brief tool called the Breakthrough Cancer Pain Assessment (BCPA) for use with cancer patients in Taiwan. The tool is intended to help medical staff assess episodes of breakthrough cancer pain in busy clinical settings.
The study has three stages. First, 14 clinical experts will review an initial set of 11 questions and assess whether they are relevant and important. Second, two medical staff members will separately interview each of 30 patients within three hours on the same day and independently record the answers to evaluate agreement between their ratings. Third, the tool will be applied in 1,043 patients recruited from multiple hospitals who are receiving short-acting opioids other than Painkyl.
In the clinical application stage, physicians will prescribe and individually adjust fentanyl buccal soluble film (Painkyl) for patients whose breakthrough pain is not meaningfully relieved within 15 minutes or whose medication administration route needs adjustment. These patients will be reassessed with the BCPA one to two weeks later. Patients with satisfactory pain relief at the initial assessment will undergo no further study procedures.
The main objectives are to evaluate the content validity and inter-rater reliability of the BCPA. A secondary objective is to determine the percentage of patients reporting meaningful pain relief within or at 15 minutes after taking Painkyl.
The planned secondary assessments also compare the pretreatment and post-treatment percentages of patients reporting meaningful pain relief within 15 minutes and their usual breakthrough pain intensity. Relief is reported by the patient using BCPA item 9; pain intensity is assessed using BCPA item 6 on a 0-to-10 scale.
The protocol describes an open-label, multicenter study comprising tool development, inter-rater reliability testing, and clinical application of the Breakthrough Cancer Pain Assessment (BCPA).
An initial set of 11 items will be developed from the literature and the opinions of oncologists experienced in managing breakthrough cancer pain. Fourteen experts in breakthrough cancer pain and/or pain instrument development will rate item relevance and importance using a four-point scale. Experts will provide comments on items rated as not or somewhat relevant or important. A Delphi process, with a maximum of four rounds, will provide feedback on item ratings and content validity. Items may be modified or deleted based on the expert review. The Delphi assessment period was approximately one month.
For inter-rater reliability testing, two medical staff members will separately interview each of 30 patients from one study site within three hours on the same day and independently record the answers. Items with low agreement or consistency will be discussed and revised before clinical application.
The clinical application stage will recruit 1,043 patients from multiple hospitals who are receiving short-acting opioids other than Painkyl. The BCPA will be used at the initial assessment to evaluate breakthrough pain control. Patients with satisfactory pain relief will undergo no further study procedures. Patients with unsatisfactory control, defined as taking more than 15 minutes to achieve meaningful relief with their current breakthrough pain medication other than Painkyl, and/or requiring a change in medication administration route at the physician's discretion, will receive Painkyl with individual dose titration and education on its use. The protocol schedules the pretreatment assessment on Day 0-1, treatment initiation on Day 1, and reassessment on Day 8-15.
The research nurse will check completed BCPA questionnaires to minimize missing data. The protocol defines a full analysis set requiring at least one BCPA assessment and an evaluable-patient set requiring both pretreatment and post-treatment assessments, in addition to informed consent, eligibility, and no protocol violations.
BCPA Tool V1.2 (14-Apr-2023) item 9 asks the patient how long rescue medication takes to provide effective pain relief. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, indicate meaningful relief within 15 minutes. Responses of no effect or more than 15 minutes indicate that this criterion is not met. Pretreatment responses concern the existing rescue medication; post-treatment responses concern Painkyl. BCPA item 6 assesses usual breakthrough pain intensity on a 0-to-10 numeric scale, where 0 is no pain and 10 is the worst pain. Higher scores indicate greater pain intensity. The questionnaire does not specify a fixed recall period.
The protocol specifies a Cochran Q test to compare pretreatment and post-treatment meaningful-relief percentages and generalized estimating equations (GEE) to examine pretreatment and post-treatment pain intensity. These analyses supplement the post-treatment meaningful-relief percentage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Criterion for the Clinical Application Stage (Stage 3):
- Patients must be receiving short-acting opioids other than Painkyl.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the clinical application stage, patients receiving short-acting opioids other than Painkyl undergo BCPA assessment. Those with unsatisfactory breakthrough pain control and/or requiring a change in medication administration route receive individually titrated Painkyl and a follow-up BCPA assessment. Patients with satisfactory pain relief at the initial assessment undergo no further study procedures. There is no comparator arm. The preceding tool-development stage includes a separate group of 30 patients. Two medical staff members separately interview each patient within three hours on the same day and independently record the answers for inter-rater reliability testing.
Drug: Fentanyl buccal soluble film
Fentanyl buccal soluble film (Painkyl) will be used for breakthrough cancer pain in patients whose current medication does not provide meaningful relief within 15 minutes and/or whose medication administration route requires adjustment. The dose will be individually titrated by the physician, starting at 200 mcg. The protocol specifies a maximum dose of 1,200 mcg per breakthrough pain episode. Patients will receive education on proper use and will be reassessed with the BCPA one to two weeks later.
Also known as: Painkyl
Item-Level Content Validity Index of the BCPA
The item-level content validity index (I-CVI) is the proportion of the 14 experts who rate a BCPA item as 3 (quite relevant) or 4 (highly relevant) on a four-point relevance scale. I-CVI will be calculated for each item during the Delphi process. Values range from 0 to 1, with higher values indicating greater expert agreement on item relevance.
Time frame: At each Delphi round during an assessment period of approximately one month (maximum of four rounds).
Scale-Level Content Validity Indices of the BCPA
Two scale-level content validity indices will be calculated for the final tool: S-CVI/Ave, the average of the item-level content validity indices, and S-CVI/UA, the proportion of items rated as 3 or 4 by all experts. Both indices range from 0 to 1, with higher values indicating greater content validity.
Time frame: At completion of the Delphi content-validation process, approximately one month after the first round (maximum of four rounds).
Inter-Rater Agreement for Categorical BCPA Items
Kappa will be calculated for each categorical BCPA item to assess agreement between ratings in 30 patients. Two medical staff members separately interview the same patient within three hours on the same day and independently record the answers.
Time frame: Day 1; the two independent assessments are completed within three hours.
Inter-Rater Consistency for Continuous BCPA Items
Intraclass correlation coefficients will be calculated for continuous BCPA items to assess consistency between ratings in 30 patients. Two medical staff members separately interview the same patient within three hours on the same day and independently record the answers.
Time frame: Day 1; the two independent assessments are completed within three hours.
Percentage of Patients With Meaningful Pain Relief Within or at 15 Minutes After Painkyl Administration
Patient-reported meaningful relief is assessed using BCPA Tool V1.2 item 9, which asks how long rescue medication takes to provide effective pain relief. At the post-treatment assessment, the medication is Painkyl. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, meet the endpoint. Responses of no effect or more than 15 minutes do not meet it. The percentage is the number of patients meeting the endpoint divided by the number of patients who received Painkyl, multiplied by 100.
Time frame: At the post-treatment BCPA assessment on Day 8-15, assessing meaningful pain relief within or at 15 minutes after Painkyl administration.
Change in the Percentage of Patients Reporting Meaningful Pain Relief Within 15 Minutes From Pretreatment to Post-treatment
The pretreatment and post-treatment percentages of patients reporting meaningful pain relief within 15 minutes will be compared using BCPA Tool V1.2 item 9. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, meet the relief criterion; no effect or more than 15 minutes does not. Pretreatment responses concern the existing rescue medication other than Painkyl; post-treatment responses concern Painkyl. The protocol defines evaluable patients as those with both pretreatment and post-treatment BCPA assessments, informed consent, eligibility, and no protocol violations. The protocol specifies a Cochran Q test for this comparison.
Time frame: Pretreatment BCPA assessment on Day 0-1 and post-treatment BCPA assessment on Day 8-15.
Change From Pretreatment to Post-treatment in Usual Breakthrough Pain Intensity
Usual breakthrough pain intensity is assessed using BCPA Tool V1.2 item 6: how painful the patient's breakthrough pain usually is. Patients select an integer from 0 to 10, where 0 means no pain and 10 means the worst pain; higher scores indicate greater pain intensity. Pretreatment and post-treatment scores will be compared. The questionnaire does not specify a fixed recall period. The protocol defines evaluable patients as those with both pretreatment and post-treatment BCPA assessments, informed consent, eligibility, and no protocol violations, and specifies generalized estimating equations (GEE) to examine the difference in pain intensity.
Time frame: Pretreatment BCPA assessment on Day 0-1 and post-treatment BCPA assessment on Day 8-15.
Ran from Aug 2023 to primary completion in Sep 2023, 1 month.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fentanyl Buccal Soluble Film
Chang Gung Memorial Hospital →